Botulinum Toxin Type A

Botulinum Toxin Brands: Formulations and Regulatory Status

Western and Korean botulinum toxin brands differ in manufacturer, formulation, vial strength, and approved indications. A clinic planning to buy botulinum toxin wholesale across brands needs documentation for each specific presentation; regulatory authorization cannot be inferred from a related product's status. A decision about how to buy botulinum toxin online begins with checking the product's authorization and documentation in the intended market. Licensed professionals may contact the Med Supply Solutions support team for general information on pricing considerations and product requirements.

Western FDA-Approved Botulinum Toxins

BOTOX® and BOTOX COSMETIC® contain onabotulinumtoxinA and are manufactured by Allergan, an AbbVie company. BOTOX Cosmetic received FDA approval for glabellar lines in 2002 and now carries additional aesthetic indications, while therapeutic BOTOX is approved for several neurological, muscular, and autonomic conditions. DYSPORT®, from Ipsen, contains abobotulinumtoxinA. It is used aesthetically for glabellar lines and therapeutically for selected conditions, including spasticity and cervical dystonia. FDA records list its original U.S. approval in 2009. XEOMIN® contains incobotulinumtoxinA. Unlike formulations supplied with accessory complexing proteins, incobotulinumtoxinA is prepared as a purified neurotoxin without them. Dosing remains product-specific and should never be assumed equivalent simply because the active toxin shares the type A designation.

Korean-Developed FDA-Approved Brands

JEUVEAU® contains prabotulinumtoxinA and was developed from Daewoong Pharmaceutical’s botulinum toxin platform. The U.S. presentation is FDA-approved for temporary improvement of moderate-to-severe glabellar lines. Hugel’s LETYBO® contains letibotulinumtoxinA. The FDA approved LETYBO on February 29, 2024, for the temporary improvement of moderate-to-severe glabellar lines in adults. [3]

Other Korean Botulinum Toxin Brands — U.S. Approval Considerations

NABOTA® is derived from the same prabotulinumtoxinA lineage, but branding and regulatory status cannot be treated as interchangeable with JEUVEAU®. The FDA has stated in warning letters that NABOTA 200U products marketed under the NABOTA name did not have approved U.S. drug applications. [1] Hugel also markets botulinum toxin products under the BOTULAX® name in other regions. BOTULAX® should not be described as FDA-approved on the basis that LETYBO® comes from the same broader product platform. The FDA has specifically identified BOTULAX-branded products offered in the U.S. without approved applications. [1] The wider Korean botulinum toxin market includes products such as LIZTOX® and Re-N-Tox™. These may be registered or marketed in Korea or other jurisdictions, but they should not be described as FDA-approved unless the exact branded product and presentation have received U.S. approval. In a November 2025 warning letter, the FDA specifically identified LIZTOX products as unapproved botulinum toxin drugs in the United States. [1]

Key Differences Across Botulinum Toxin Brands

Different types of botulinum toxin share a similar core mechanism, but botulinum toxin brands can vary in formulation, potency assay, dilution instructions, approved indications, and dosing requirements. These distinctions matter even when products belong to the same toxin category.

Botulinum Toxin Units Are Not Interchangeable

Among these clinical distinctions, this is the one most tied to patient safety. Manufacturers establish botulinum toxin units using manufacturer-specific biological assays, so dosing should always follow the prescribing information for the exact product being administered. Clinical literature has explored approximate relationships when practitioners switch between formulations. IncobotulinumtoxinA and onabotulinumtoxinA have often been studied at approximately 1:1, while published comparisons of abobotulinumtoxinA with onabotulinumtoxinA commonly fall around 2.5:1 to 3:1. [2] These ratios describe findings from selected clinical studies, not authorized conversion formulas. BOTOX® vs DYSPORT® is a useful example: similar treatment goals do not make potency units interchangeable. A botulinum toxin units comparison must refer to each product's prescribing information.

Formulation Differences

BOTOX®, DYSPORT®, XEOMIN®, JEUVEAU®, LETYBO®, and other type A toxins vary in manufacturing process and formulation. XEOMIN® is notable for containing purified botulinum neurotoxin without accessory complexing proteins. Other products are formulated differently and may contain different excipients or toxin-associated proteins. When comparing formulations, practitioners also consider onset, diffusion, and treatment duration. These characteristics are influenced by several factors, including dose, dilution, injection volume, muscle anatomy, administration technique, and treatment area.

Approved Uses of Botulinum Toxin Type A

Approved indications for botulinum toxin type A differ by brand and jurisdiction. In neuromodulator wholesale planning, the intended clinical use should be matched to the product's current local labeling rather than assumed from another formulation's authorization.

Aesthetic Uses

Treatment of glabellar lines, the vertical frown lines between the eyebrows, is one of the most common approved cosmetic indications across major neuromodulator brands. Depending on the product, approved aesthetic uses may also include:

• Forehead lines
• Lateral canthal lines, commonly called crow’s feet
• Other facial lines covered by the applicable prescribing information

Injectors also use botulinum toxin in areas such as the masseter, brow, chin, perioral region, or platysmal bands. Where those uses are not included in the relevant product labeling, they should be treated as off-label rather than presented as universally approved indications.

Therapeutic Uses

Some botulinum toxin products have a much broader range of medical indications. Depending on the specific brand and jurisdiction, these can include:

• Chronic migraine
• Cervical dystonia
• Blepharospasm
• Limb spasticity
• Hyperhidrosis
• Overactive bladder
• Other neuromuscular or autonomic disorders

BOTOX®, for example, carries FDA-approved therapeutic indications well beyond facial aesthetics. Approval cannot automatically transfer to another toxin simply because both contain botulinum toxin type A.

Botulinum Toxin Safety Profile

All botulinum toxin products require appropriate practitioner training, anatomical knowledge, product-specific dosing, and careful patient assessment. Common adverse effects vary with the treatment area but can include:

• Injection-site pain, redness, swelling, or bruising
• Headache
• Temporary eyelid or brow ptosis
• Local muscle weakness
• Asymmetry

FDA-approved botulinum toxin products also carry a boxed warning that the toxin’s effects may spread distantly. Botulinum toxin activity may spread beyond the injection site and produce botulism-like symptoms, including generalized muscle weakness, difficulty swallowing, difficulty speaking, or respiratory compromise. The FDA describes this warning as applying to approved botulinum toxin drugs as a class. [1] Practitioners should also confirm contraindications and precautions in the individual product's prescribing information before administration. During product intake, they should review shipping temperature records and verify that storage requirements were maintained according to the manufacturer's instructions.

Botulinum Toxin Regulatory Status

As of mid-2026, several botulinum toxin type A products hold FDA approval for temporary improvement of moderate-to-severe glabellar lines:

• BOTOX COSMETIC® (onabotulinumtoxinA)
• DYSPORT® (abobotulinumtoxinA)
• XEOMIN® (incobotulinumtoxinA)
• JEUVEAU® (prabotulinumtoxinA)
• DAXXIFY® (daxibotulinumtoxinA-lanm)
• LETYBO® (letibotulinumtoxinA) [3]

The FDA approved DAXXIFY for glabellar lines in September 2022 and LETYBO in February 2024. This list should not be interpreted to mean that every international brand containing the same or related toxin is also FDA-approved. In particular, NABOTA®, BOTULAX®, LIZTOX®, Re-N-Tox™, and other internationally marketed Korean presentations each require their own regulatory assessment. In November 2025, the FDA issued warning letters about websites marketing unapproved and misbranded botulinum toxin drugs. [1] To order botulinum toxin online through lawful channels, a clinic must verify the exact presentation's authorization, the source's legitimacy, and applicable professional requirements.

Neuromodulator Wholesale: Product Documentation and Availability

Licensed healthcare professionals considering whether to purchase botulinum toxin online can contact the Med Supply Solutions support team for information on specific product presentations and supporting records available for review.

Frequently Asked Questions

Are botulinum toxin units interchangeable between brands?

No. Botulinum toxin units are brand-specific and are not interchangeable. Published conversion estimates can provide clinical context when switching products, but practitioners should always follow the dosing and reconstitution instructions for the exact brand being administered. [2]

Which botulinum toxins are FDA-approved?

For the aesthetic treatment of moderate-to-severe glabellar lines, FDA-approved type A products include BOTOX® Cosmetic, DYSPORT®, XEOMIN®, JEUVEAU®, DAXXIFY®, and LETYBO®. International products such as LIZTOX® and Re-N-Tox™ should not be described as FDA-approved without a specific approved U.S. application.

Is NABOTA® the same as JEUVEAU®?

They share the same prabotulinumtoxinA development platform, but regulatory branding matters. JEUVEAU® is the FDA-approved U.S. product, whereas the FDA has specifically identified NABOTA 200U products sold under the NABOTA name as lacking an approved U.S. application.

What is the difference between Western and Korean botulinum toxins?

The primary distinctions include manufacturing origin, brand formulation, regulatory footprint, clinical evidence base, vial presentation, and market availability. Both groups may contain botulinum toxin type A, but approval and dosing requirements apply to the specific brand, not the toxin category as a whole.

How can a clinic confirm it is reviewing the correct BTX-A presentation?

Check the exact brand name, vial strength, and formulation against the accompanying product records, especially when related formulations are marketed under different names. If a practice intends to order botulinum toxin wholesale, it should also confirm lot identity and temperature-handling records. The Med Supply Solutions support team can respond to general inquiries like pricing and documentation. For licensed healthcare professionals only. The content of this page is provided for informational purposes and does not constitute medical advice.

Citations

[1] U.S. Food and Drug Administration. “FDA Warns Companies Over Illegal Marketing of Botox and Related Products.” U.S. Food and Drug Administration, 5 Nov. 2025.   [2] Scaglione, Francesco. “Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.” Toxins vol. 8,3 65. 4 Mar. 2016, doi:10.3390/toxins8030065   [3] U.S. Food and Drug Administration. “Drug Trials Snapshots: LETYBO.” FDA, www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo.